

**CTSA**

Clinical & Translational  
Science Awards Program

# Addressing Common Statistical Issues

**Karen Bandeen-Roche**

**Hurley-Dorrier Professor and Chair**

**Johns Hopkins Bloomberg School of Public Health**

**Lead, CTSA Workgroup on Inclusion of Older Adults  
as a Model for Special Populations**



Center for Leading  
Innovation & Collaboration

**CTSA**

Clinical & Translational  
Science Awards Program



**CLIC**  
Center for Leading  
Innovation & Collaboration

# **Study and data analytic design: Lenses to magnify clinical and translational research that includes older adults**

CTSA

Clinical & Translational  
Science Awards Program

# Do older adults seriously complicate study analysis and interpretation?

- Common wisdom
  - Older adults only selectively participate
  - Older adults' data are “messy”
  - Older adult health complicates study interpretation




CLIC  
Center for Leading  
Innovation & Collaboration

# Do older adults seriously complicate study analysis and interpretation?

- Older adult inclusion has real benefits to study analysis and interpretation!
  - They are **dedicated** study participants
  - Heightened event rates may enhance study **power**
  - Addressing complexities challenging interpretation in older adults provides a **roadmap for addressing complexities** in others
  - Clearly understanding mechanisms in older adults as a “point of the spear” for adverse outcomes may provide general **mechanistic insights**

# Do older adults seriously complicate study analysis and interpretation?

- Clearly understanding mechanisms in older adults as a “point of the spear” for adverse outcomes may provide general mechanistic insights



CTSA

Clinical & Translational  
Science Awards Program

# Objectives

- Sampling of highest-profile challenges
- Three methodological strategies
  - Pilot studies
  - Design
  - Data analysis
- Take home messages / Challenges / Gaps



CLIC  
Center for Leading  
Innovation & Collaboration

# Selective participation / Dropout

## Study-wise

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Mis-represents the intended population</b></li><li>• <b>Sample loss</b></li><li>• <i>Anecdote: Is there honestly negligible frailty incidence as people age?</i></li></ul>				

# Selective participation / Dropout

## Study-wise

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"> <li>• <b>Mis-represents the intended population</b></li> <li>• <b>Sample loss</b></li> <li>• <i>Anecdote: Is there honestly negligible frailty incidence as people age?</i></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Solutions generalize to younger participants!</b></li> </ul>			

# Selective participation / Dropout

## Study-wise

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"> <li>• <b>Mis-represents the intended population</b></li> <li>• <b>Sample loss</b></li> <li>• <i>Anecdote: Is there honestly negligible frailty incidence as people age?</i></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Solutions generalize to younger participants!</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Interviews, qualitative research to learn about participant barriers and solutions</b></li> </ul>		

# Selective participation / Dropout

## Study-wise

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"> <li>• <b>Mis-represents the intended population</b></li> <li>• <b>Sample loss</b></li> <li>• <i>Anecdote: Is there honestly negligible frailty incidence as people age?</i></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Solutions generalize to younger participants!</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Interviews, qualitative research to learn about participant barriers and solutions</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Sample size accounting for incomplete recruitment / retention</b></li> <li>• <b>Innovations to reduce barriers</b></li> <li>• <b>Foot-in-door questionnaire</b></li> <li>• <b>Auxiliary data</b></li> </ul>	

# Selective participation / Dropout

## Study-wise

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"> <li>• <b>Mis-represents the intended population</b></li> <li>• <b>Sample loss</b></li> <li>• <i>Anecdote: Is there honestly negligible frailty incidence as people age?</i></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Solutions generalize to younger participants!</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Interviews, qualitative research to learn about participant barriers and solutions</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Sample size accounting for incomplete recruitment / retention</b></li> <li>• <b>Innovations to reduce barriers</b></li> <li>• <b>Foot-in-door questionnaire</b></li> <li>• <b>Auxiliary data</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>“Crosswalks” the observed data to the intended population</b></li> <li>• Inverse-probability weighting</li> <li>• Selection modeling</li> <li>• Sensitivity analysis</li> </ul>

# Selective participation

Measure-wise: Same as study-wise, plus:

THREATS	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"> <li>• <b>Bias in estimating relationships</b></li> <li>• <b>Loss of power and precision</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Coordinator-focused interviews</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Prioritize key measures early in the assessment</b></li> <li>• <i>Anecdote: Running out of time</i></li> <li>• <b>Record reasons for data missingness</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Maximize data inclusion, minimize biases</b> <ul style="list-style-type: none"> <li>• Multiple imputation</li> <li>• FIML</li> <li>• Acknowledging “couldn’t” versus “didn’t”</li> </ul> </li> </ul>

# Competing risks / Death

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Flawed, misleading interpretation of study findings</b></li><li>• <i>Anecdote: Hydrochloroquine?</i></li></ul>				

CTSA

Clinical & Translational  
Science Awards Program



Center for Leading  
Innovation & Collaboration

# Competing risks / Death

CTSA

Clinical & Translational  
Science Awards Program

 **CLIC**  
Center for Leading  
Innovation & Collaboration

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Flawed, misleading interpretation of study findings</b></li><li>• <i>Anecdote: Hydrochloroquine?</i></li></ul>	<ul style="list-style-type: none"><li>• <b>Richer delineation of treatment impacts</b></li></ul>			

# Competing risks / Death

CTSA

Clinical & Translational  
Science Awards Program



Center for Leading  
Innovation & Collaboration

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Flawed, misleading interpretation of study findings</b></li><li>• <i>Anecdote: Hydrochloroquine?</i></li></ul>	<ul style="list-style-type: none"><li>• <b>Richer delineation of treatment impacts</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Document, prepare for death rate</b></li></ul>		

# Competing risks / Death

CTSA

Clinical & Translational  
Science Awards Program



Center for Leading  
Innovation & Collaboration

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Flawed, misleading interpretation of study findings</b></li><li>• <i>Anecdote: Hydrochloroquine?</i></li></ul>	<ul style="list-style-type: none"><li>• <b>Richer delineation of treatment impacts</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Document, prepare for death rate</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Sample size considerations</b></li><li>• <b>Interim measurements</b></li></ul>	

# Competing risks / Death

CTSA

Clinical & Translational  
Science Awards Program

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Flawed, misleading interpretation of study findings</b></li><li>• <i>Anecdote: Hydrochloroquine?</i></li></ul>	<ul style="list-style-type: none"><li>• <b>Richer delineation of treatment impacts</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Document, prepare for death rate</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Sample size considerations</b></li><li>• <b>Interim measurements</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Aims to explicitly account for “competition”</b></li><li>• <b>Address all risks</b><ul style="list-style-type: none"><li>• Composite outcomes</li><li>• Cause-specific relative hazard</li><li>• Subdistribution (incidence)</li><li>• Latent variable methods</li></ul></li></ul>



Center for Leading  
Innovation & Collaboration

# Measurement issues

CTSA

Clinical & Translational  
Science Awards Program



THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Conflation of intended outcome with measurement modality</b></li><li>• <b>Invalid inferences</b></li><li>• <i>Anecdote: Cognitive testing and sensory impairment</i></li></ul>	<ul style="list-style-type: none"><li>• <b>Wearables</b></li><li>• <b>Sensors</b></li><li>• <b>Implantables</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Multi-trait multi-method studies</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Bridging subsets</b></li><li>• <b>Thoughtful tailoring of measures to, and across, subpopulations</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Aims to faithfully characterize the target of measurement</b></li><li>• <b>Bridge measurement differences</b></li><li>• <b>Explore error ramifications for effect estimation</b><ul style="list-style-type: none"><li>• Harmonization, latent variables</li><li>• Error “calibration”</li><li>• Modeling of variance in terms of the mean</li><li>• “Functional” data analysis</li></ul></li></ul>

**CTSA**

Clinical & Translational  
Science Awards Program



Center for Leading  
Innovation & Collaboration

# Multimorbidity, Polypharmacy, Etc.

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li><b>Inadequate delineation of altered treatment mechanisms / subgroup effects</b></li></ul>				

# Multimorbidity, Polypharmacy, Etc.

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Inadequate delineation of altered treatment mechanisms / subgroup effects</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Insights regarding mechanisms</b></li><li>• <b>“Leverage” heterogeneity creates for estimating relationships</b></li></ul>			

# Multimorbidity, Polypharmacy, Etc.

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Inadequate delineation of altered treatment mechanisms / subgroup effects</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Insights regarding mechanisms</b></li><li>• <b>“Leverage” heterogeneity creates for estimating relationships</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Literature review</b></li><li>• <b>Secondary data analyses to identify key suspects</b></li></ul>		

# Multimorbidity, Polypharmacy, Etc.

CTSA

Clinical & Translational  
Science Awards Program



Center for Leading  
Innovation & Collaboration

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"><li>• <b>Inadequate delineation of altered treatment mechanisms / subgroup effects</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Insights regarding mechanisms</b></li><li>• <b>“Leverage” heterogeneity creates for estimating relationships</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Literature review</b></li><li>• <b>Secondary data analyses to identify key suspects</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Sample size considerations by strata</b></li><li>• <b>Identification of variables where strength can be borrowed</b></li><li>• <i>Anecdote: Flu vaccines and baseline pro-inflammatory, immune status</i></li></ul>	

# Multimorbidity, Polypharmacy, Etc.

CTSA

Clinical & Translational  
Science Awards Program



Center for Leading  
Innovation & Collaboration

THREATS	OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"> <li>• <b>Inadequate delineation of altered treatment mechanisms / subgroup effects</b></li> </ul>	<ul style="list-style-type: none"> <li>• Insights regarding mechanisms</li> <li>• “Leverage” heterogeneity creates for estimating relationships</li> </ul>	<ul style="list-style-type: none"> <li>• Literature review</li> <li>• Secondary data analyses to identify key suspects</li> </ul>	<ul style="list-style-type: none"> <li>• Sample size considerations by strata</li> <li>• Identification of variables where strength can be borrowed</li> <li>• <i>Anecdote: Flu vaccines and baseline pro-inflammatory, immune status</i></li> </ul>	<ul style="list-style-type: none"> <li>• Reduce noise due to heterogeneity</li> <li>• Leverage heterogeneity to learn about mechanisms                             <ul style="list-style-type: none"> <li>• Baseline covariate adjustment (<i>trials</i>)</li> <li>• Propensity scores, instrumental variables, sensitivity analyses (<i>observational studies</i>)</li> <li>• Testing, advanced model selection to identify effect modification</li> <li>• Mixture models</li> </ul> </li> </ul>

# Leveraging Older Age as the “Point of the Spear” on Health

OPPORTUNITIES	PILOT STUDIES	DESIGN	ANALYSIS
<ul style="list-style-type: none"> <li>• <b>Insights into treatment / health mechanisms</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Hone protocols to make design elements practical</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Include gerontological outcomes in assessments</b> <ul style="list-style-type: none"> <li>• Synthetic – markers of overall functional / health status</li> <li>• Geriatric “vital signs”</li> <li>• Function, cognition, frailty, sarcopenia, falls, ...</li> </ul> </li> <li>• <b>Measure outcomes repeatedly</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Consider effect modification by age (akin to multimorbidity, polypharmacy, etc.)</b></li> <li>• <b>Backward time analyses</b></li> <li>• <b>Trajectory, transition analyses</b></li> </ul>

# Exhortation for our colleagues

- Engage statisticians and epidemiologists
  - They will love contributing to thinking about optimal strategies.
- It's not all bad
  - Added insights lurk
  - Solutions generalize to younger participants
  - Complexities relative to younger participants overblown?
- There's a lot of good!
  - Older adults are dedicated study participants
  - Added heterogeneity translates into heightened leverage, event rates in subsets
  - Aging is a point of the spear that can generate insights earlier in the lifespan

CTSA

Clinical & Translational  
Science Awards Program

# Do older adults seriously complicate study analysis and interpretation?

- Gaps
  - Study designs to buffer informative dropout
  - Study designs to maximize information while limiting burden
  - Addressing heterogeneous treatment, exposure effects
  - **Additional challenges?**



CLIC  
Center for Leading  
Innovation & Collaboration